Evaluation of 12-Lipoxygenase (12-LOX) and Plasminogen Activator Inhibitor 1 (PAI-1) as Prognostic Markers in Prostate Cancer

Table 3

Normal expression of 12-LOX and PAI-1 and normalized expression to TBG and PLT in prostate cancer patients with different Gleason grade.

	Gleason grade ≤ 6; Mean ± SD; (median)	Gleason grade > 6; Mean ± SD; (median)	𝑃
12-LOX (ng/mL)	158.5±354.0; (56)	112.8±133.7; (63)	0.8
PAI-1 (U/mL)	577.3±442.2; (428)	687.3±568.6; (499)	0.3
TBG (kU)	6.5±4.5; (7.75)	5.5±2.7; (5.4)	0.4
PLT (10^3/mm^3)	209.9±49.9; (210)	241.3±97.1; (219)	0.2
12-LOX/TBG	35.6±80.8; (8.8)	30.7±71.7; (11.4)	0.5
PAI-1/TBG	135.8±155.3; (80)	188.6±227.9; (90)	0.6
TBG/PLT	0.03±0.02; (0.03)	0.025±0.01; (0.02)	0.3
12-LOX/PLT	0.75±1.6; (0.25)	0.47±0.53; (0.27)	0.9
PAI-1/PLT	2.95±2.6; (2.1)	3.0±2.6; (2.4)	0.7